Cargando…

mTOR Overactivation in Mesenchymal cells Aggravates CCl(4)− Induced liver Fibrosis

Hepatic stellate cells are of mesenchymal cell type located in the space of Disse. Upon liver injury, HSCs transactivate into myofibroblasts with increase in expression of fibrillar collagen, especially collagen I and III, leading to liver fibrosis. Previous studies have shown mTOR signaling is acti...

Descripción completa

Detalles Bibliográficos
Autores principales: Shan, Lanlan, Ding, Yan, Fu, You, Zhou, Ling, Dong, Xiaoying, Chen, Shunzhi, Wu, Hongyuan, Nai, Wenqing, Zheng, Hang, Xu, Wanfu, Bai, Xiaochun, Jia, Chunhong, Dai, Meng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5098141/
https://www.ncbi.nlm.nih.gov/pubmed/27819329
http://dx.doi.org/10.1038/srep36037
_version_ 1782465725180411904
author Shan, Lanlan
Ding, Yan
Fu, You
Zhou, Ling
Dong, Xiaoying
Chen, Shunzhi
Wu, Hongyuan
Nai, Wenqing
Zheng, Hang
Xu, Wanfu
Bai, Xiaochun
Jia, Chunhong
Dai, Meng
author_facet Shan, Lanlan
Ding, Yan
Fu, You
Zhou, Ling
Dong, Xiaoying
Chen, Shunzhi
Wu, Hongyuan
Nai, Wenqing
Zheng, Hang
Xu, Wanfu
Bai, Xiaochun
Jia, Chunhong
Dai, Meng
author_sort Shan, Lanlan
collection PubMed
description Hepatic stellate cells are of mesenchymal cell type located in the space of Disse. Upon liver injury, HSCs transactivate into myofibroblasts with increase in expression of fibrillar collagen, especially collagen I and III, leading to liver fibrosis. Previous studies have shown mTOR signaling is activated during liver fibrosis. However, there is no direct evidence in vivo. The aim of this study is to examine the effects of conditional deletion of TSC1 in mesenchymal on pathogenesis of liver fibrosis. Crossing mice bearing the floxed TSC1 gene with mice harboring Col1α2-Cre-ER(T) successfully generated progeny with a conditional knockout of TSC1 (TSC1 CKO) in collagen I expressing mesenchymal cells. TSC1 CKO and WT mice were subjected to CCl(4), oil or CCl(4)+ rapamycin treatment for 8 weeks. TSC1 CKO mice developed pronounced liver fibrosis relative to WT mice, as examined by ALT, hydroxyproline, histopathology, and profibrogenic gene. Absence of TSC1 in mesenchymal cells induced proliferation and prevented apoptosis in activated HSCs. However, there were no significant differences in oil-treated TSC1 CKO and WT mice. Rapamycin, restored these phenotypic changes by preventing myofibroblasts proliferation and enhancing their apoptosis. These findings revealed mTOR overactivation in mesenchymal cells aggravates CCl(4)− induced liver fibrosis and the rapamycin prevent its occurance.
format Online
Article
Text
id pubmed-5098141
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-50981412016-11-10 mTOR Overactivation in Mesenchymal cells Aggravates CCl(4)− Induced liver Fibrosis Shan, Lanlan Ding, Yan Fu, You Zhou, Ling Dong, Xiaoying Chen, Shunzhi Wu, Hongyuan Nai, Wenqing Zheng, Hang Xu, Wanfu Bai, Xiaochun Jia, Chunhong Dai, Meng Sci Rep Article Hepatic stellate cells are of mesenchymal cell type located in the space of Disse. Upon liver injury, HSCs transactivate into myofibroblasts with increase in expression of fibrillar collagen, especially collagen I and III, leading to liver fibrosis. Previous studies have shown mTOR signaling is activated during liver fibrosis. However, there is no direct evidence in vivo. The aim of this study is to examine the effects of conditional deletion of TSC1 in mesenchymal on pathogenesis of liver fibrosis. Crossing mice bearing the floxed TSC1 gene with mice harboring Col1α2-Cre-ER(T) successfully generated progeny with a conditional knockout of TSC1 (TSC1 CKO) in collagen I expressing mesenchymal cells. TSC1 CKO and WT mice were subjected to CCl(4), oil or CCl(4)+ rapamycin treatment for 8 weeks. TSC1 CKO mice developed pronounced liver fibrosis relative to WT mice, as examined by ALT, hydroxyproline, histopathology, and profibrogenic gene. Absence of TSC1 in mesenchymal cells induced proliferation and prevented apoptosis in activated HSCs. However, there were no significant differences in oil-treated TSC1 CKO and WT mice. Rapamycin, restored these phenotypic changes by preventing myofibroblasts proliferation and enhancing their apoptosis. These findings revealed mTOR overactivation in mesenchymal cells aggravates CCl(4)− induced liver fibrosis and the rapamycin prevent its occurance. Nature Publishing Group 2016-11-07 /pmc/articles/PMC5098141/ /pubmed/27819329 http://dx.doi.org/10.1038/srep36037 Text en Copyright © 2016, The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Article
Shan, Lanlan
Ding, Yan
Fu, You
Zhou, Ling
Dong, Xiaoying
Chen, Shunzhi
Wu, Hongyuan
Nai, Wenqing
Zheng, Hang
Xu, Wanfu
Bai, Xiaochun
Jia, Chunhong
Dai, Meng
mTOR Overactivation in Mesenchymal cells Aggravates CCl(4)− Induced liver Fibrosis
title mTOR Overactivation in Mesenchymal cells Aggravates CCl(4)− Induced liver Fibrosis
title_full mTOR Overactivation in Mesenchymal cells Aggravates CCl(4)− Induced liver Fibrosis
title_fullStr mTOR Overactivation in Mesenchymal cells Aggravates CCl(4)− Induced liver Fibrosis
title_full_unstemmed mTOR Overactivation in Mesenchymal cells Aggravates CCl(4)− Induced liver Fibrosis
title_short mTOR Overactivation in Mesenchymal cells Aggravates CCl(4)− Induced liver Fibrosis
title_sort mtor overactivation in mesenchymal cells aggravates ccl(4)− induced liver fibrosis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5098141/
https://www.ncbi.nlm.nih.gov/pubmed/27819329
http://dx.doi.org/10.1038/srep36037
work_keys_str_mv AT shanlanlan mtoroveractivationinmesenchymalcellsaggravatesccl4inducedliverfibrosis
AT dingyan mtoroveractivationinmesenchymalcellsaggravatesccl4inducedliverfibrosis
AT fuyou mtoroveractivationinmesenchymalcellsaggravatesccl4inducedliverfibrosis
AT zhouling mtoroveractivationinmesenchymalcellsaggravatesccl4inducedliverfibrosis
AT dongxiaoying mtoroveractivationinmesenchymalcellsaggravatesccl4inducedliverfibrosis
AT chenshunzhi mtoroveractivationinmesenchymalcellsaggravatesccl4inducedliverfibrosis
AT wuhongyuan mtoroveractivationinmesenchymalcellsaggravatesccl4inducedliverfibrosis
AT naiwenqing mtoroveractivationinmesenchymalcellsaggravatesccl4inducedliverfibrosis
AT zhenghang mtoroveractivationinmesenchymalcellsaggravatesccl4inducedliverfibrosis
AT xuwanfu mtoroveractivationinmesenchymalcellsaggravatesccl4inducedliverfibrosis
AT baixiaochun mtoroveractivationinmesenchymalcellsaggravatesccl4inducedliverfibrosis
AT jiachunhong mtoroveractivationinmesenchymalcellsaggravatesccl4inducedliverfibrosis
AT daimeng mtoroveractivationinmesenchymalcellsaggravatesccl4inducedliverfibrosis